Erythrocytosis

Erythrocytosis is pathological elevation of red blood cell (RBC) mass producing increased blood viscosity and the cardiovascular morbidity profile that follows. The clinical threshold in adult males is haematocrit (HCT) above 52% per Endocrine Society TRT guidelines; frank polycythaemia (HCT >54%) carries documented stroke, MI, and DVT signal in the cardiovascular outcomes literature (Ohlander et al. 2018, Sex Med Rev).

Reference frame:

– Adult male HCT reference: 38.8–50%
– Watch zone (TRT/cruise): 52–54%. Tighten monitoring; no immediate intervention
– Action threshold: >54%. Phlebotomy indicated
– Hard stop: >58%. Frank polycythaemia; immediate intervention plus dose reduction

Mechanism on testosterone-based protocols:

Exogenous testosterone elevates red cell mass through two convergent pathways. Direct stimulation of renal erythropoietin (EPO) release drives bone marrow erythropoiesis. Suppression of hepcidin — the iron-regulating hormone — releases stored iron from macrophages and intestinal enterocytes, removing the iron-availability brake on erythropoiesis. Bachman et al. 2014, J Gerontol documented the hepcidin suppression mechanism. The combined EPO-up plus hepcidin-down signal produces dose-dependent erythrocytosis steeper than EPO alone would predict.

The rise is not optional, not avoidable through hydration, and not a sign of something “going wrong” — it is the expected pharmacological response. Compound-specific impact varies: testosterone produces moderate elevation, boldenone undecylenate produces steeper rise (mechanism includes additional direct erythropoietic action), nandrolone produces moderate elevation similar to testosterone, trenbolone produces moderate elevation plus haem-pigment renal artefact that complicates serum creatinine interpretation.

Cardiovascular mechanism — why the threshold matters:

Whole-blood viscosity rises exponentially rather than linearly with HCT. At HCT 58%, plasma viscosity is approximately double the value at 48%. Higher viscosity raises shear stress on vascular endothelium, activates the coagulation cascade through endothelial mechanotransduction, and drives prothrombotic shift. Kanayama et al. 2018, Mayo Clin Proc reviewed cardiovascular mortality patterns in long-term AAS users and identified erythrocytosis as the consistent biomarker present at sudden cardiac death and stroke presentations.

The risk is more reliable than the lipid signal because erythrocytosis acts acutely (over weeks-to-months), while atherosclerotic risk integrates across years.

Mitigation interventions in leverage order:

– Whole-blood donation — 450 mL drops HCT by ~3 percentage points; resets trajectory for 8–12 weeks. US: every 56 days. EU: every 3 months male.
– Ferritin surveillance — repeated phlebotomy depletes iron stores. Target ferritin 50–150 ng/mL; supplement when trending toward floor.
– Dose reduction — 20–30% testosterone dose reduction lowers HCT over 8–12 weeks. Insufficient as acute intervention.
– Low-dose aspirin (81 mg/day) — antiplatelet prophylaxis above HCT 52%. ASCEND 2018, NEJM. Evidence base extrapolated from primary CV prevention trials.
– E2 management — iatrogenic hypoestrogenaemia from aggressive AI dosing accelerates HCT rise. Maintaining sensitive E2 at 25–40 pg/mL preserves the estrogenic counter-regulation.
– Hydration — measurement correction only, not treatment. Dehydrated draws read 2–3 percentage points high.

Confounders requiring differential workup:

Obstructive sleep apnea (OSA) mimics testosterone-driven HCT elevation through identical EPO-up pathway. Users presenting with unexpectedly high HCT despite modest testosterone doses warrant sleep-study workup before attributing to protocol — clinical signs include heavy snoring, daytime somnolence, partner-reported apneic episodes, untreated hypertension, BMI >30. JAK2 mutation (polycythaemia vera) is the rare differential in unusual cases.